Department of Critical Care Unit, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002, Sungang west Road, Futian District, Shenzhen, China.
College of Nursing, Gannan Medical University, No. 1 Hexie Road, Rongjiang New area, Ganzhou, China.
Dig Liver Dis. 2021 Feb;53(2):153-157. doi: 10.1016/j.dld.2020.09.007. Epub 2020 Sep 17.
The association between metabolic-associated fatty liver disease (MAFLD) and disease progression in patients with the coronavirus disease 2019 (COVID-19) are unclear.
To explore the association between MAFLD and the severity of COVID-19 by meta-analysis.
We conducted a literature search using PubMed, EMBASE, Medline (OVID), and MedRxiv from inception to July 6, 2020. Newcastle-Ottawa Scale (NOS) and Stata 14.0 were used for quality assessment of included studies as well as for performing a pooled analysis.
A total of 6 studies with 1,293 participants were included after screening. Four studies reported the prevalence of MAFLD patients with COVID-19, with a pooled prevalence of 0.31 for MAFLD (95CI 0.28, 0.35, I = 38.8%, P = 0.179). MAFLD increased the risk of COVID-19 disease severity, with a pooled OR of 2.93 (95CI 1.87, 4.60, I = 34.3%, P = 0.166).
In this meta-analysis, we found that a high percentage of patients with COVID-19 had MAFLD. Meanwhile, MAFLD increased the risk of disease progression among patients with COVID-19. Thus, better intensive care and monitoring are needed for MAFLD patients infected by SARS-COV-2.
代谢相关脂肪性肝病（MAFLD）与 2019 年冠状病毒病（COVID-19）患者疾病进展之间的关系尚不清楚。
通过荟萃分析探讨 MAFLD 与 COVID-19 严重程度之间的关系。
我们从 2020 年 7 月 6 日起，使用 PubMed、EMBASE、Medline（OVID）和 MedRxiv 进行文献检索。使用纽卡斯尔-渥太华量表（NOS）和 Stata 14.0 对纳入研究进行质量评估，并进行汇总分析。
经过筛选，共纳入了 6 项研究，共 1293 名参与者。其中 4 项研究报告了 MAFLD 患者 COVID-19 的患病率，MAFLD 的总体患病率为 0.31（95%CI 0.28，0.35，I = 38.8%，P = 0.179）。MAFLD 增加了 COVID-19 疾病严重程度的风险，汇总 OR 为 2.93（95%CI 1.87，4.60，I = 34.3%，P = 0.166）。
在这项荟萃分析中，我们发现 COVID-19 患者中有相当高比例的患者患有 MAFLD。同时，MAFLD 增加了 COVID-19 患者疾病进展的风险。因此，感染 SARS-COV-2 的 MAFLD 患者需要更好的重症监护和监测。
